...Presentation of Preclinical Data Supporting FPI-2059 and...
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced the presentation of preclinical data that provide further support of its clinical stage FPI-2059, a neurotensin receptor 1 (NTSR1) targeted alpha therapy (TAT), and add...